Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that…
- DUBLIN, Oct. 2, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or…
- EAST HANOVER, N.J., Sept. 30, 2025 — Novartis announced today that Rhapsido (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain…
- HORSHAM, PA, (September 29, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of children six years and older who also weigh at least…
- Budapest, Hungary and London, UK, 29 September 2025 – Gedeon Richter Plc. (“Richter”) and Hikma Pharmaceuticals Plc. along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (“Hikma”) announce today that…
- September 29, 2025 — Kedrion Biopharma announced today that it has received FDA approval for Qivigy®, a new 10% Immunoglobulin for intravenous use, indicated for treatment of adults with Primary humoral Immunodeficiency (PI), a serious and…
- TUESDAY, Oct. 7, 2025 — Ambient trichloroethylene (TCE) is associated with an increased risk for Parkinson disease (PD), according to a study published online Oct. 1 in Neurology.Brittany Krzyzanowski, Ph.D., from the Barrow Neurological Institute…
- TUESDAY, Oct. 7, 2025 — The experience at a radiology department during a mass casualty incident (MCI) following the Oct. 7, 2023, attack in Southern Israel has been described in a report published online Sept. 30 in Radiology. Gal Ben-Arie, M.D…
- TUESDAY, Oct. 7, 2025 — Children and adolescents are twice as likely to experience long COVID after being infected for the second time, according to a study published online Sept. 30 in The Lancet Infectious Diseases. Bingyu Zhang, from the…
- TUESDAY, Oct. 7, 2025 — The rate of gabapentin prescribing slowed after 2016, but is still increasing, according to a research letter published online Sept. 30 in the Annals of Internal Medicine. Andrea E. Strahan, Ph.D., from the U.S. Centers for…
- TUESDAY, Oct. 7, 2025 — Seventeen years after human papillomavirus (HPV) vaccine introduction, population-level effectiveness and herd protection are robust, according to a study published online Sept. 29 in JAMA Pediatrics. Aislinn DeSieghardt…
- TUESDAY, Oct. 7, 2025 — A robotic-assisted bronchoscope (RAB) can reach very small tumors growing in hard-to-reach parts of the lung, according to a study presented at the annual congress of the European Respiratory Society, held from Sept. 27 to…
Thông tin từ The Pharma Letter
- Massachusetts, USA-based Affinia Therapeutics, an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced it has closed a $40 million Series C financing.
- Privately-held cell therapy company Orca Bio has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking approval for Orca-T.
- The ground shifted under China’s drugmakers when volume-based procurement cut through list prices. Margins tightened, business models wobbled, and strategy decks were rewritten overnight. The domestic market still offers scale, but the old assumption that scale guaranteed profit no longer holds.
- UK pharma major AstraZeneca has entered into a multi-target partnership with Algen Biotechnologies, the California, USA biotech announced.
- US biotech AeroRx Therapeutics has secured $21 million in Series A financing to advance its lead program, AERO-007, into Phase IIb testing in chronic obstructive pulmonary disease. The round was led by Avalon BioVentures, with support from Correlation Ventures and Alexandria Venture Investments.
- Italian biotech NanoPhoria Bioscience has announced the successful first close of its 83.5 million euros ($97.4 million) Series A financing round.
Thông tin từ BioPharmaDive
- Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.
- The company set terms for an offering with the help of a little-used section of the Securities Act that would enable its IPO to price automatically in 20 days.
- The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable, additional sign of regulatory flexibility for gene therapies.
- The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.
- The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.
- A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug acquisition paid more dividends and a Vertex veteran became Stoke’s full-time CEO.
Thông tin từ STAT News
- A federal appeals court ruling could allow Medicare to negotiate prices for larger number of drugs.
- Pharma companies are hoping to announce deals of their own with President Trump as soon as this week, sources told STAT.
- At the Supreme Court, a majority of justices seemed poised to rule against a Colorado law banning so-called conversion therapy.
- Peter Marks, the former top vaccine regulator at the FDA, has joined Eli Lilly — a move likely to rile up critics of the revolving door between FDA and industry
- This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
- And more biotech news from The Readout newsletter today.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 07 October 2025; doi:10.1038/d41573-025-00163-2Designer peptide retunes channel function
- Nature Reviews Drug Discovery, Published online: 07 October 2025; doi:10.1038/d41573-025-00162-3Macrocyclic peptides challenge cell cycle defects
- Nature Reviews Drug Discovery, Published online: 30 September 2025; doi:10.1038/s41573-025-01291-5In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging viral and lipid nanoparticle platforms, early clinical proof of concept and potential applications beyond cancer.
- Nature Reviews Drug Discovery, Published online: 23 September 2025; doi:10.1038/d41573-025-00160-5Designing new antibiotics
- Nature Reviews Drug Discovery, Published online: 23 September 2025; doi:10.1038/d41573-025-00158-zTargeting GPR31 to treat MASH
- Nature Reviews Drug Discovery, Published online: 23 September 2025; doi:10.1038/d41573-025-00157-0Blocking SLC38A2 lowers blood pressure